Literature DB >> 1445979

Extraparenchymal neurocysticercosis: report of five cases and review of management.

J C Bandres1, A C White, T Samo, E C Murphy, R L Harris.   

Abstract

Neurocysticercosis due to parenchymal cysts carries a good prognosis regardless of therapy. Extraparenchymal neurocysticercosis (including ventricular, spinal, and subarachnoid types) carries a poorer prognosis. Most extraparenchymal cases present with hydrocephalus. Medical treatment alone in doses and schedules developed for parenchymal disease is frequently unsuccessful. For ventricular disease, most cases can be managed with shunting procedures either alone or together with the administration of antiparasitic agents (e.g., praziquantel or albendazole), without extirpation of the cysts. Subarachnoid disease was formerly associated with a case fatality rate of about 50%. However, with the combination of shunting procedures for hydrocephalus, antiparasitic agents, and, in some cases, surgical extirpation of the cysts, the prognosis is much improved. Spinal cysticercosis can be either leptomeningeal (which responds like subarachnoid disease) or intramedullary. For all forms of neurocysticercosis, the role of antiparasitic agents needs to be better defined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445979     DOI: 10.1093/clind/15.5.799

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

Review 1.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

Review 2.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

3.  Brain granulomas in neurocysticercosis patients are associated with a Th1 and Th2 profile.

Authors:  B I Restrepo; J I Alvarez; J A Castaño; L F Arias; M Restrepo; J Trujillo; C H Colegial; J M Teale
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Neurocysticercosis.

Authors:  Vincent C Marconi; Hector H Garcia; Joel T Katz
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

5.  Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients.

Authors:  O H Del Brutto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 6.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

7.  Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series.

Authors:  Graciela Cárdenas; Roger Carrillo-Mezo; Helgi Jung; Edda Sciutto; Jose Luis Soto Hernandez; Agnès Fleury
Journal:  BMC Neurol       Date:  2010-03-04       Impact factor: 2.474

Review 8.  Immunology of Taenia solium taeniasis and human cysticercosis.

Authors:  H H Garcia; S Rodriguez; J S Friedland
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

Review 9.  Management of neurocysticercosis.

Authors:  Terrence Riley; A C White
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Diagnosis and treatment of neurocysticercosis.

Authors:  Christina M Coyle; Herbert B Tanowitz
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.